

Antibiotic Susceptibility Survey

Number Tested / % Susceptible

	C. freundii		C. koseri		K. aerogenes		E. cloacae		E. coli		K. oxytoca	
Amikacin	-	-	-	-	-	-	-	-	121	93%	-	-
Ampicillin	-	-	-	-	-	-	-	-	11917	65%	-	-
Ampicillin/Sul	-	-	162	94%	-	-	-	-	11913	70%	685	50%
Aztreonam	411	82%	163	99%	301	79%	735	76%	11917	94%	685	96%
Cefazolin	-	-	163	94%	-	-	-	-	11917	84%	685	35%
Cefepime	411	99%	163	100%	301	93%	761	~98%	11917	95%	684	97%
Cefoxitin	-	-	162	97%	-	-	-	-	11913	96%	685	97%
Ceftazidime	411	82%	163	100%	301	79%	735	76%	11917	94%	685	97%
Ceftaz/Avi	-	-	-	-	-	-	-	-	-	-	-	-
Ceftol/Tazo	-	-	-	-	-	-	-	-	-	-	-	-
Ceftriaxone	411	81%	163	99%	301	78%	735	74%	11917	94%	685	95%
Cefuroxime	-	-	162	93%	301	71%	-	-	11913	93%	685	93%
Ciprofloxacin	411	91%	163	99%	301	95%	735	93%	11917	84%	685	97%
Ertapenem	411	98%	163	100%	301	93%	735	81%	11916	100%	685	99%
Gentamicin	411	98%	163	98%	301	100%	735	97%	11917	91%	685	98%
Imipenem	-	-	-	-	-	-	-	-	-	-	-	-
Levofloxacin	411	94%	163	99%	301	96%	735	97%	11917	89%	685	99%
Meropenem	411	100%	163	100%	301	97%	735	98%	11917	100%	685	99%
*Nitrofurantoin	379	95%	142	46%	262	25%	591	29%	11394	98%	564	90%
Piperac/Tazo	411	82%	163	96%	301	75%	735	75%	11917	98%	685	94%
Tetracycline	411	86%	162	96%	301	94%	735	92%	11913	84%	685	95%
Tigecycline	68	99%	29	97%	71	96%	289	97%	771	100%	196	99%
Tobramycin	411	99%	163	100%	301	99%	735	97%	11917	91%	685	97%
Trim/Sulfa	411	90%	163	97%	301	98%	735	90%	11917	85%	685	95%

~ SDD included in % Susceptible

* Urinary tract isolates only.

- Not tested or known to be clinically ineffective

† Includes only the first isolate of each species from each patient.

Low number of isolates. Results are less statistically valid.

ESBL incidence rate for 2024: 4.76%
 CRE incidence rate for 2024: 0.46%
 CP-CRE incidence rate for 2024: 0.02%

Reprints and additional information available at:

<https://nordx.testcatalog.org/>

Antibiotic Susceptibility Survey

Number Tested / % Susceptible

	K. pneumoniae		M. morganii		P. mirabilis		P.aeruginosa		S.marcescens		Ac. baumannii	
Amikacin	17	82%	-	-	11	55%	1097	100%	-	-	45	100%
Ampicillin	-	-	-	-	1192	84%	-	-	-	-	-	-
Ampicillin/Sul	2102	81%	224	25%	1192	91%	-	-	-	-	45	98%
Aztreonam	2107	90%	224	98%	1192	99%	1193	83%	364	99%	-	-
Cefazolin	2107	83%	-	-	1192	2%	-	-	-	-	-	-
Cefepime	2107	90%	223	100%	1192	99%	1193	95%	363	99%	45	87%
Cefoxitin	2102	93%	224	80%	1192	99%	-	-	-	-	-	-
Ceftazidime	2107	89%	224	90%	1192	98%	1193	93%	364	99%	-	-
Ceftaz/Avi	-	-	-	-	-	-	-	-	-	-	-	-
Ceftol/Tazo	-	-	-	-	-	-	1193	98%	-	-	-	-
Ceftriaxone	2107	90%	224	94%	1192	98%	-	-	364	96%	45	49%
Cefuroxime	2102	86%	-	-	1192	97%	-	-	-	-	-	-
Ciprofloxacin	2107	86%	224	84%	1192	85%	1193	83%	364	95%	45	96%
Ertapenem	2107	98%	224	100%	1192	98%	-	-	364	98%	-	-
Gentamicin	2107	94%	224	90%	1192	94%	779	98%	364	99%	45	89%
Imipenem	-	-	-	-	-	-	-	-	-	-	-	-
Levofloxacin	2107	91%	224	85%	1192	86%	1193	83%	364	98%	45	98%
Meropenem	2697	100%	224	100%	-	-	1193	94%	364	99%	45	98%
*Nitrofurantoin	1892	46%	-	-	-	-	-	-	-	-	-	-
Piperac/Tazo	2107	88%	224	99%	1192	99%	1193	91%	364	96%	-	-
Tetracycline	2102	84%	-	-	-	-	-	-	-	-	23	96%
Tigecycline	304	93%	-	-	-	-	-	-	215	92%	-	-
Tobramycin	2107	93%	224	93%	1192	93%	1193	99%	364	86%	45	98%
Trim/Sulfa	2107	86%	224	87%	1192	87%	-	-	-	-	45	93%

~ SDD included in % Susceptible

* Urinary tract isolates only.

- Not tested or known to be clinically ineffective

† Includes only the first isolate of each species from each patient.

Low number of isolates. Results are less statistically valid.

ESBL incidence rate for 2024: 4.76%
 CRE incidence rate for 2024: 0.46%
 CP-CRE incidence rate for 2024: 0.02%

Reprints and additional information available at:

<https://nordx.testcatalog.org/>

Antibiotic Susceptibility Survey

Number Tested / % Susceptible

	E. faecalis		E. faecium		S. aureus		S. epidermidis		***MSSA***		***MRSA***	
Ampicillin	1743	100%	256	19%	-	-	-	-	-	-	-	-
Cefazolin	-	-	-	-	3902	71%	1084	49%	3003	98%	1160	1%
Ceftaroline	-	-	-	-	3899	99%	-	-	3000	100%	1161	98%
Clindamycin	-	-	-	-	3685	76%	649	59%	2825	81%	1103	64%
Daptomycin	1743	83%	121	~94%	3747	100%	1089	100%	2890	100%	1117	100%
Doxycycline	1743	36%	256	48%	3903	96%	1084	84%	3003	97%	1161	92%
Erythromycin	476	12%	95	15%	3653	54%	633	33%	2800	70%	1092	16%
Gentamicin	-	-	-	-	3904	97%	1013	100%	3005	98%	1161	96%
Levofloxacin	1512	88%	192	14%	3903	79%	1084	76%	3003	94%	1161	42%
Linezolid	1743	99%	256	96%	3904	100%	1089	100%	3005	100%	1161	100%
Minocycline	-	-	-	-	3648	97%	632	98%	2795	98%	1092	94%
Moxifloxacin	-	-	-	-	3729	80%	741	79%	2868	94%	1111	44%
*Nitrofurantoin	1512	100%	-	-	2163	100%	564	100%	1664	100%	630	100%
Oxacillin	-	-	-	-	3904	71%	1089	49%	3005	98%	1161	1%
Penicillin	-	-	-	-	-	-	-	-	-	-	-	-
Quinupr/Dalfo	-	-	-	-	-	-	-	-	-	-	-	-
#Rifampin	-	-	-	-	3904	100%	1089	99%	3005	100%	1161	99%
Tetracycline	1512	24%	192	14%	3903	88%	1084	77%	3003	91%	1161	81%
Tigecycline	449	100%	-	-	3648	97%	-	-	2795	100%	1092	90%
Trim/Sulfa	-	-	-	-	3904	89%	-	-	3005	94%	1161	75%
Vancomycin	1743	96%	256	39%	3904	100%	1089	100%	3005	100%	1161	100%
Gent Synergy	1743	89%	256	97%	-	-	-	-	-	-	-	-
Strep Synergy	1743	90%	256	49%	-	-	-	-	-	-	-	-

	H. influenzae		S. pneumoniae	
	# Tested	Suscep.	# Tested	Suscep.
Amoxicillin	-	-	204	99%
Ampicillin	18	72%	-	-
Amox/Clav	-	-	-	-
Cefepime	-	-	204	95%
Cefotaxime	-	-	200	100%
Ceftriaxone	18	100%	202	100%
Clindamycin	-	-	203	89%
Erythromycin	-	-	203	69%
Levofloxacin	-	-	204	98%
Linezolid	-	-	205	100%
Meropenem	17	100%	205	90%
Moxifloxacin	-	-	204	98%
Penicillin	-	-	153	100%
Tetracycline	-	-	204	72%
Trim/Sulfa	-	-	205	74%
Vancomycin	-	-	205	100%

~ SDD included in % Susceptible

* Urinary tract isolates only.

- Not tested or known to be clinically ineffective

† Includes only the first isolate of each species from each patient.

Rifampin should not be used alone for therapy.

Low number of isolates. Results are less statistically valid.

Routine testing of Haemophilus was discontinued in 2016. HI is tested from sterile sites or upon request.